Meeting
2024 ASCO Genitourinary Cancers Symposium
Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study.
Authors
Ugo De Giorgi
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy
Ugo De Giorgi , Arun Azad , Karim Fizazi , Nobuaki Matsubara , Fred Saad , Jae Young Joung , Peter C.C. Fong , Robert J. Jones , Stefanie Zschaebitz , Jan Oldenburg , Neal D. Shore , Curtis Dunshee , Joan Carles , Andre P. Fay , Paul Cislo , Melissa Kirker , Cynthia G. Healy , Alexander Niyazov , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT03395197
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 116)
DOI
10.1200/JCO.2024.42.4_suppl.116
Abstract #
116
Poster Bd #
E9
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
First Author: Karim Fizazi
First Author: Arun Azad